Alex Therapeutics is a digital health company founded in 2018 with the mission to provide clinically validated digital tools that support people living with complex conditions such as rare diseases and cancer. They focus on delivering evidence-based therapy companion apps that address the unique challenges of disease and treatment-specific management, aiming to help individuals live more confidently and thrive.

Specializing in oncology and rare diseases, Alex Therapeutics partners with pharmaceutical companies to create companion apps that enhance patient outcomes by supporting medication management and mental health challenges. They combine the latest technology, including AI integration, with patient-centric design to deliver personalized care. Their solutions comply with global medical device regulations, including EU MDR and FDA standards.

The company develops modular therapy companions that can be customized for any patient population or treatment, emphasizing behavior change for better mental and physical health. Their flagship product, Almee™, is a digital therapy shown in clinical trials to significantly reduce anxiety in patients with rare diseases like pulmonary fibrosis. They also offer medication adherence tools, symptom tracking, and CBT-based psychological support modules.

Alex Therapeutics is headquartered in Stockholm, Sweden, with a team of 20+ professionals including psychologists, engineers, and market access experts. They have a significant partnership network in pharma and maintain an active presence on LinkedIn. They invite potential partners and customers to book demos via email for more information.